Q-omics provides the consensus-scored TBXAS1 profile across patient tissues and cancer cell-line models. TBXAS1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TBXAS1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TBXAS1 protein abundance shows 27,140 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where TBXAS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBXAS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBXAS1 survival associations across molecular data types. TBXAS1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBXAS1 RNA expression–survival associations across cancer types. High TBXAS1 expression shows unfavorable associations in UVM, STAD, LGG and KIRP, but favorable associations in HNSC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TBXAS1 RNA expression.
This table summarizes TBXAS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TBXAS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBXAS1 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, KIRP, THCA and COAD. The KIRC box plot shows higher TBXAS1 RNA expression in tumor versus normal tissue (log2 FC = +1.952, t-test p < 0.001).
This table shows molecular features associated with TBXAS1 in patient tissues and cancer cell lines. In patient samples, TBXAS1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TBXAS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
